KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Liabilities: 2011-2025

Historic Total Liabilities for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $2.2 billion.

  • Sarepta Therapeutics' Total Liabilities fell 8.64% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 8.64%. This contributed to the annual value of $2.4 billion for FY2024, which is 1.26% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Total Liabilities is $2.2 billion, which was down 6.42% from $2.3 billion recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Total Liabilities high stood at $2.7 billion for Q4 2022, and its period low was $2.2 billion during Q3 2025.
  • Moreover, its 3-year median value for Total Liabilities was $2.3 billion (2023), whereas its average is $2.3 billion.
  • Its Total Liabilities has fluctuated over the past 5 years, first increased by 24.29% in 2022, then decreased by 13.94% in 2023.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Total Liabilities stood at $2.2 billion in 2021, then rose by 23.58% to $2.7 billion in 2022, then decreased by 12.33% to $2.4 billion in 2023, then rose by 1.26% to $2.4 billion in 2024, then declined by 8.64% to $2.2 billion in 2025.
  • Its last three reported values are $2.2 billion in Q3 2025, $2.3 billion for Q2 2025, and $2.3 billion during Q1 2025.